These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 35569559)

  • 1. Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies.
    Alshaikh RA; Waeber C; Ryan KB
    Adv Drug Deliv Rev; 2022 Aug; 187():114342. PubMed ID: 35569559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in Formulation Approaches for Sustained Drug Delivery to the Posterior Segment of the Eye.
    Biswas A; Choudhury AD; Bisen AC; Agrawal S; Sanap SN; Verma SK; Mishra A; Kumar S; Bhatta RS
    AAPS PharmSciTech; 2023 Oct; 24(8):217. PubMed ID: 37891392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new era in posterior segment ocular drug delivery: Translation of systemic, cell-targeted, dendrimer-based therapies.
    Kannan RM; Pitha I; Parikh KS
    Adv Drug Deliv Rev; 2023 Sep; 200():115005. PubMed ID: 37419213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye.
    Bisht R; Jaiswal JK; Rupenthal ID
    Med Hypotheses; 2017 Jun; 103():5-9. PubMed ID: 28571808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal hydrogels for sustained release of therapeutic proteins.
    Ilochonwu BC; Urtti A; Hennink WE; Vermonden T
    J Control Release; 2020 Oct; 326():419-441. PubMed ID: 32717302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug delivery methods for posterior segment disease.
    Hsu J
    Curr Opin Ophthalmol; 2007 May; 18(3):235-9. PubMed ID: 17435432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodegradable Polymer-Based Drug-Delivery Systems for Ocular Diseases.
    Tsung TH; Tsai YC; Lee HP; Chen YH; Lu DW
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical Drug Delivery to the Posterior Segment of the Eye: Addressing the Challenge of Preclinical to Clinical Translation.
    Rodrigues GA; Lutz D; Shen J; Yuan X; Shen H; Cunningham J; Rivers HM
    Pharm Res; 2018 Oct; 35(12):245. PubMed ID: 30374744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases.
    Shatz W; Aaronson J; Yohe S; Kelley RF; Kalia YN
    Expert Opin Drug Deliv; 2019 Jan; 16(1):43-57. PubMed ID: 30488721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posterior segment drug delivery for the treatment of exudative age-related macular degeneration and diabetic macular oedema.
    Wong CW; Wong TT
    Br J Ophthalmol; 2019 Oct; 103(10):1356-1360. PubMed ID: 31040133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental and mathematical approaches for drug delivery for the treatment of wet age-related macular degeneration.
    Chacin Ruiz EA; Swindle-Reilly KE; Ford Versypt AN
    J Control Release; 2023 Nov; 363():464-483. PubMed ID: 37774953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications.
    Booth BA; Vidal Denham L; Bouhanik S; Jacob JT; Hill JM
    Drugs Aging; 2007; 24(7):581-602. PubMed ID: 17658909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in ocular drug delivery systems.
    Kang-Mieler JJ; Rudeen KM; Liu W; Mieler WF
    Eye (Lond); 2020 Aug; 34(8):1371-1379. PubMed ID: 32071402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implants for drug delivery to the posterior segment of the eye: a focus on stimuli-responsive and tunable release systems.
    Yasin MN; Svirskis D; Seyfoddin A; Rupenthal ID
    J Control Release; 2014 Dec; 196():208-21. PubMed ID: 25307997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and strategies for ocular posterior diseases therapy via non-invasive advanced drug delivery.
    Qi Q; Wei Y; Zhang X; Guan J; Mao S
    J Control Release; 2023 Sep; 361():191-211. PubMed ID: 37532148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical challenges for developing long acting intravitreal medicines.
    Awwad S; Henein C; Ibeanu N; Khaw PT; Brocchini S
    Eur J Pharm Biopharm; 2020 Aug; 153():130-149. PubMed ID: 32445965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting formulation strategies for protein and peptide delivery in the treatment of PSED.
    Garkal A; Bangar P; Rajput A; Pingale P; Dhas N; Sami A; Mathur K; Joshi S; Dhuri S; Parikh D; Mutalik S; Mehta T
    J Control Release; 2022 Oct; 350():538-568. PubMed ID: 36030993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel drug delivery systems for retinal diseases. A review.
    Lee SS; Robinson MR
    Ophthalmic Res; 2009; 41(3):124-35. PubMed ID: 19321933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in ocular drug delivery: emphasis on the posterior segment.
    Kang-Mieler JJ; Osswald CR; Mieler WF
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1647-60. PubMed ID: 24975820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next generation therapeutics for retinal neurodegenerative diseases.
    Appell MB; Pejavar J; Pasupathy A; Rompicharla SVK; Abbasi S; Malmberg K; Kolodziejski P; Ensign LM
    J Control Release; 2024 Mar; 367():708-736. PubMed ID: 38295996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.